Scarica l'app Stockscreener
100.44
0.47%
-0.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Yahoo Finance
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader - MyChesCo
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz - simplywall.st
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Yahoo Finance
Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (NASDAQ:INCY) Insider Sells $277,400.00 in Stock - MarketBeat
Incyte principal accounting officer Tray Thomas sells shares worth $336k - Investing.com
Incyte (NASDAQ:INCY) Stock Price Down 3.4%Time to Sell? - MarketBeat
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - RTTNews
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido - PharmiWeb.com
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - PharmiWeb.com
Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatme - GuruFocus
Incyte (INCY) Secures Japanese Approval for Minjuvi Combination Therapy - GuruFocus
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Yahoo Finance
Entry Recap: Can Incyte Corporation stock beat market expectations this quarterJuly 2025 Snapshot & Weekly Top Gainers Trade List - moha.gov.vn
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer - MyChesCo
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
VP Iyengar Files To Sell 52,941 Of Incyte Corp [INCY] - TradingView — Track All Markets
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Why Incyte Corporation (ICY) stock stays on buy listsMarket Performance Report & High Conviction Buy Zone Alerts - DonanımHaber
Can Incyte Corporation stock hit analyst price targetsWatch List & Free Weekly Watchlist of Top Performers - DonanımHaber
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st
Incyte Corp EVP Sells Over $5.6 Million in Company Stock - TradingView — Track All Markets
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance
Incyte to Present at Upcoming Investor Conference - Business Wire
EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology
Incyte wins European approval of Minjuvi in FL - The Pharma Letter
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - BioSpace
Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq
Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus
Minjuvi approved in EU for relapsed follicular lymphoma treatment - Investing.com
Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Minjuvi approved in EU for relapsed follicular lymphoma treatment By Investing.com - Investing.com South Africa
INCYTE wins European approval for Minjuvi cancer treatment - StreetInsider
(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress? - simplywall.st
VP Morrissey Files To Sell 54,008 Of Incyte Corp [INCY] - TradingView — Track All Markets
Is Incyte Corp Gaining or Losing Market Support? - Benzinga
Incyte (INCY): Reassessing Valuation After Breakthrough Therapy Status and Positive INCA033989 Phase 1 Data - simplywall.st
Shareholder Stamoulis Files To Sell 187,690 Of Incyte Corp [INCY] - TradingView — Track All Markets
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is Incyte Stock Outperforming the Nasdaq? - Yahoo Finance
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo
Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately By Investing.com - Investing.com Canada
Incyte Corp EVP & Chief Scientific Officer Sells Shares - TradingView — Track All Markets
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Incyte Corp Announces Board Retirement - TradingView — Track All Markets
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Business Wire
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
1.93%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):